Combining a CDK4/6 Inhibitor With Pemetrexed Inhibits Cell Proliferation and Metastasis in Human Lung Adenocarcinoma

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) have shown limited success as single agents in lung adenocarcinoma (LUAD).
• Disappointing outcomes necessitate exploration of synergistic combination therapies involving CDK4/6i.
• This study investigates the combined anti-tumor effects of ribociclib (a CDK4/6i) and pemetrexed in LUAD.

Purpose of the Study:

• To evaluate the synergistic anti-tumor efficacy of combining ribociclib and pemetrexed in LUAD.
• To elucidate the underlying mechanisms of this combination therapy.
• To assess the impact on cancer cell proliferation, apoptosis, migration, and invasion.

Main Methods:

• In vitro studies using LUAD cell lines treated with varying doses of ribociclib and pemetrexed.
• Assessment of anti-tumor effects via growth inhibition assays.
• Flow cytometry for cell cycle distribution and apoptosis analysis.
• Wound healing and Transwell assays for migration and invasion.
• Western blotting for protein expression analysis.
• In vivo validation using mice xenograft models.

Main Results:

• Pemetrexed induced S-phase arrest, while ribociclib caused G1-phase arrest, leading to synergistic anti-tumor effects.
• The combination significantly enhanced apoptosis via the caspase/bcl-2 signaling pathway.
• Combined treatment markedly inhibited LUAD cell migration and invasion.
• In vivo studies confirmed the potent anti-cancer activity of the combination.

Conclusions:

• The combination of ribociclib and pemetrexed demonstrates significant potential as a novel therapeutic strategy for LUAD.
• This combination therapy effectively inhibits cancer proliferation, invasion, and metastasis.
• Further clinical investigation is warranted to establish this as an effective treatment for LUAD patients.